Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDOSE: Reduced dose enzalutamide in frail mCRPC patients
NCT03927391Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Change in fatigue at 6 weeks. Started May 2019; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03927391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927391.